中国角膜移植市场现状研究分析与发展前景预测报告

Core Viewpoint - Corneal transplantation is a highly successful surgical procedure that replaces damaged corneal tissue with healthy donor corneas, addressing various eye conditions and restoring vision [1][2]. Market Overview - The corneal transplantation market in China is experiencing rapid growth, with the market size projected to reach 824 million yuan in 2024 and 1.286 billion yuan by 2031, reflecting a compound annual growth rate (CAGR) of 6.51% from 2025 to 2031 [4]. - Corneal diseases are a significant cause of blindness, second only to cataracts, making corneal transplantation a critical treatment option in ophthalmic microsurgery [3]. Market Dynamics - The supply of donor corneas is limited and unevenly distributed across regions, particularly affecting rural areas in central and western China [3]. - Recent improvements in eye bank systems, professional training, public awareness, and advancements in artificial cornea technologies are driving market development [3]. Market Segmentation - In 2024, penetrating keratoplasty is expected to dominate the market with a share of 61.41%, followed by lamellar keratoplasty at 21.60% [8]. - The ophthalmology specialty hospitals are the leading institutions for corneal transplantation, with their market size projected to grow from 619 million yuan in 2024 to 952 million yuan by 2031, at a CAGR of 6.33% [9]. Competitive Landscape - Major players in the domestic artificial cornea market include Shenzhen Ainier Cornea Engineering, Mihe Medical, Yueqing Regenerative Medicine, and Jiayue Meishi Biotechnology, with the top four companies holding approximately 87.59% of the market share in 2024 [7]. - The industry is transitioning towards diversified supply, precise treatment, and convenient services, with expectations of maintaining an annual growth rate of over 6% in the coming 5 to 10 years [9]. Supply Chain Analysis - The upstream supply chain primarily consists of voluntarily donated corneas organized by the Red Cross and hospitals, while artificial corneas are produced using high-purity medical-grade polymers and bioactive scaffold materials [11][12]. - Downstream, specialized ophthalmology hospitals and large public hospital eye centers are the main institutions performing the transplants, requiring long-term follow-up care for patients [12].